Comparison of immune responses to the O-specific polysaccharide and lipopolysaccharide of Vibrio cholerae O1 in Bangladeshi adult patients with cholera

Clinical and Vaccine Immunology

Volumn 19, Issue 11, 2012, Pages 1712-1721

  Johnson, Russell A ^a   Uddin, Taher ^a   Aktar, Amena ^a   Mohasin, M ^a   Alam, Mohammad Murshid ^a   Chowdhury, Fahima ^a   Harris, Jason B ^b,c   LaRocque, Regina C ^b,c   Bufano, Meagan Kelly ^b   Yu, Yanan ^b,c   Wu Freeman, Ying ^b   Leung, Daniel T ^a,b,c   Sarracino, David ^d   Krastins, Bryan ^d   Charles, Richelle C ^b,c   Xu, Peng ^e   Kováč, Pavol ^e   Calderwood, Stephen B ^b,c   Qadri, Firdausi ^a   Ryan, Edward T ^b,c,f  

^a INTERNATIONAL CENTRE FOR DIARRHOEAL DISEASE RESEARCH   (Bangladesh)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Thermo Fisher Scientific   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; BOVINE SERUM ALBUMIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LIPOPOLYSACCHARIDE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BANGLADESH; CHOLERA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CONVALESCENCE; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; MUCOSAL IMMUNITY; PRIORITY JOURNAL; VIBRIO CHOLERAE;

ADULT; ANTIBODIES, BACTERIAL; BANGLADESH; BLOOD BACTERICIDAL ACTIVITY; CHOLERA; FEMALE; HUMANS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MALE; O ANTIGENS; VIBRIO CHOLERAE O1;

EID: 84868231122     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00321-12     Document Type: Article

References (53)

1. Alam MM, et al. 2011. Antigen-specific memory B-cell responses in Bangladeshi adults after one- or two-dose oral killed cholera vaccination and comparison with responses in patients with naturally acquired cholera. Clin. Vaccine Immunol. 18:844-850.
2. Albert MJ, Alam K, Rahman AS, Huda S, Sack RB. 1994. Lack of cross-protection against diarrhea due to Vibrio cholerae O1 after oral immunization of rabbits with V. cholerae O139 Bengal. J. Infect. Dis. 169: 709-710. (Pubitemid 24063035)
3. Ali M, Emch M, Park JK, Yunus M, Clemens J. 2011. Natural cholera infection-derived immunity in an endemic setting. J. Infect. Dis. 204:912-918.
4. Charles RC, et al. 2009. Comparative proteomic analysis of the PhoP regulon in Salmonella enterica serovar Typhi versus Typhimurium. PLoS One 4:e6994. doi:10.1371/journal.pone.0006994.
5. Cox AD, Brisson JR, Varma V, Perry MB. 1996. Structural analysis of the lipopolysaccharide from Vibrio cholerae O139. Carbohydr. Res. 290:43-58. (Pubitemid 26261213)
6. Cox AD, Perry MB. 1996. Structural analysis of the O-antigen-core region of the lipopolysaccharide from Vibrio cholerae O139. Carbohydr. Res. 290:59-65. (Pubitemid 26261214)
7. Czerkinsky C, et al. 1987. IgA antibody-producing cells in peripheral blood after antigen ingestion: evidence for a common mucosal immune system in humans. Proc. Natl. Acad. Sci. U. S. A. 84:2449-2453. (Pubitemid 17082366)
8. Fattom A, et al. 1993. Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A. Infect. Immun. 61:1023-1032. (Pubitemid 23059663)
9. Finkelstein RA. 1962. Vibriocidal antibody inhibition (VAI) analysis: a technique for the identification of the predominant vibriocidal antibodies in serum and for the detection and identification of Vibrio cholerae antigens. J. Immunol. 89:264-271.
10. Glass RI, et al. 1985. Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J. Infect. Dis. 151:236-242. (Pubitemid 15162711)
11. Gupta RK, Szu SC, Finkelstein RA, Robbins JB. 1992. Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified by lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin. Infect. Immun. 60:3201-3208.
12. Gupta RK, Taylor DN, Bryla DA, Robbins JB, Szu SC. 1998. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect. Immun. 66:3095-3099. (Pubitemid 28303102)
13. Hankins JV, Madsen JA, Giles DK, Brodbelt JS, Trent MS. 2012. Amino acid addition to Vibrio cholerae LPS establishes a link between surface remodeling in Gram-positive and Gram-negative bacteria. Proc. Natl. Acad. Sci. U. S. A. 109:8722-8727.
14. Harris AM, et al. 2009. Antigen-specific memory B-cell responses to Vibrio cholerae O1 infection in Bangladesh. Infect. Immun. 77:3850-3856.
15. Harris JB, et al. 2008. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl. Trop. Dis. 2:e221. doi:10.1371/journal.pntd.0000221. (Pubitemid 352002926)
16. Hisatsune K, et al. 1993. O-antigenic lipopolysaccharide of Vibrio cholerae O139 Bengal, a new epidemic strain for recent cholera in the Indian subcontinent. Biochem. Biophys. Res. Commun. 196:1309-1315. (Pubitemid 23347592)
17. Ito T, Higuchi T, Hirobe M, Hiramatsu K, Yokota T. 1994. Identification of a novel sugar, 4-amino-4,6-dideoxy-2-O-methylmannose in the lipopolysaccharide of Vibrio cholerae O1 serotype Ogawa. Carbohydr. Res. 256:113-128. (Pubitemid 24103141)
18. Jayasekera CR, et al. 2008. Cholera toxin-specific memory B cell responses are induced in patients with dehydrating diarrhea caused by Vibrio cholerae O1. J. Infect. Dis. 198:1055-1061.
19. Kall L, Canterbury JD, Weston J, Noble WS, MacCoss MJ. 2007. Semi-supervised learning for peptide identification from shotgun proteomics datasets. Nat. Methods 4:923-925. (Pubitemid 350042380)
20. Kendall EA, et al. 2010. Development of immunoglobulin M memory to both a T-cell-independent and a T-cell-dependent antigen following infection with Vibrio cholerae O1 in Bangladesh. Infect. Immun. 78:253-259.
21. Koelle K, Rodo X, Pascual M, Yunus M, Mostafa G. 2005. Refractory periods and climate forcing in cholera dynamics. Nature 436:696-700. (Pubitemid 41117271)
22. Kossaczka Z, et al. 2000. Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice. Infect. Immun. 68:5037-5043.
23. Kuchta A, et al. 2011. Vibrio cholerae O1 infection induces proinflammatory CD4+ T-cell responses in blood and intestinal mucosa of infected humans. Clin. Vaccine Immunol. 18:1371-1377.
24. Leung DT, Chowdhury F, Calderwood SB, Qadri F, Ryan ET. 2012. Immune responses to cholera in children. Expert Rev. Anti Infect. Ther. 10:435-444.
25. Leung DT, et al. 2012. Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin. Vaccine Immunol. 19:690-698.
26. Levine MM, et al. 1981. Duration of infection-derived immunity to cholera. J. Infect. Dis. 143:818-820. (Pubitemid 11062231)
27. Lopez MF, et al. 2011. Mass spectrometric discovery and selective reaction monitoring (SRM) of putative protein biomarker candidates in first trimester Trisomy 21 maternal serum. J. Proteome Res. 10:133-142.
28. Losonsky GA, et al. 1996. Factors influencing secondary vibriocidal immune responses: relevance for understanding immunity to cholera. Infect. Immun. 64:10-15. (Pubitemid 26009334)
29. Mosley WH, Aziz KM, Rahman AS, Chowdhury AK, Ahmed A. 1973. Field trials of monovalent Ogawa and Inaba cholera vaccines in rural Bangladesh-three years of observation. Bull. World Health Organ. 49: 381-387.
30. Mosley WH, McCormack WM, Ahmed A, Chowdhury AK, Barui RK. 1969. Report of the 1966-67 cholera vaccine field trial in rural East Pakistan. 2. Results of the serological surveys in the study population-the relationship of case rate to antibody titre and an estimate of the inapparent infection rate with Vibrio cholerae. Bull. World Health Organ. 40:187-197.
31. Mosley WH, et al. 1970. The 1968-1969 cholera-vaccine field trial in rural East Pakistan. Effectiveness of monovalent Ogawa and Inaba vaccines and a purified Inaba antigen, with comparative results of serological and animal protection tests. J. Infect. Dis. 121(Suppl):121-129.
32. Neoh SH, Rowley D. 1970. The antigens of Vibrio cholerae involved in the vibriocidal action of antibody and complement. J. Infect. Dis. 121:505-513.
33. Patel SM, et al. 2012. Memory B cell responses to Vibrio cholerae O1 lipopolysaccharide are associated with protection against infection in household contacts of cholera patients in Bangladesh. Clin. Vaccine Immunol. 19:842-848.
34. Pollard AJ, Perrett KP, Beverley PC. 2009. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat. Rev. Immunol. 9:213-220.
35. Provenzano D, Kov?̌ P, Wade WF. 2006. The ABCs (antibody, B cells, and carbohydrate epitopes) of cholera immunity: considerations for an improved vaccine. Microbiol. Immunol. 50:899-927. (Pubitemid 44974647)
36. Qadri F, et al. 1999. Lipopolysaccharide- and cholera toxin-specific subclass distribution of B-cell responses in cholera. Clin. Diagn. Lab. Immunol. 6:812-818. (Pubitemid 29529971)
37. Qadri F, et al. 2000. Enterotoxin-specific immunoglobulin E responses in humans after infection or vaccination with diarrhea-causing enteropathogens. Infect. Immun. 68:6077-6081.
38. Qadri F, et al. 1997. Immune response to the mannose-sensitive hemagglutinin in patients with cholera due to Vibrio cholerae O1 and O0139. Clin. Diagn. Lab. Immunol. 4:429-434. (Pubitemid 27321775)
39. Qadri F, et al. 1995. Comparison of the vibriocidal antibody response in cholera due to Vibrio cholerae O139 Bengal with the response in cholera due to Vibrio cholerae O1. Clin. Diagn. Lab Immunol. 2:685-688.
40. Qadri F, et al. 2002. Increased levels of inflammatory mediators in children and adults infected with Vibrio cholerae O1 and O139. Clin. Diagn. Lab. Immunol. 9:221-229. (Pubitemid 34226010)
41. Qadri F, et al. 2003. Antigen-specific immunoglobulin A antibodies secreted from circulating B cells are an effective marker for recent local immune responses in patients with cholera: comparison to antibodysecreting cell responses and other immunological markers. Infect. Immun. 71:4808-4814. (Pubitemid 36919952)
42. Qadri F, et al. 1997. Comparison of immune responses in patients infected with Vibrio cholerae O139 and O1. Infect. Immun. 65:3571-3576. (Pubitemid 27398109)
43. Saha D, et al. 2004. Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh. J. Infect. Dis. 189:2318-2322. (Pubitemid 38757206)
44. Shamsuzzaman S, et al. 2009. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses. Vaccine 27:1386-1392.
45. Stroeher UH, Karageorgos LE, Morona R, Manning PA. 1992. Serotype conversion in Vibrio cholerae O1. Proc. Natl. Acad. Sci. U. S. A. 89:2566-2570.
46. Svennerholm AM, et al. 1984. Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J. Infect. Dis. 149:884-893. (Pubitemid 14082150)
47. Uddin T, et al. 2011. Mucosal immunologic responses in cholera patients in Bangladesh. Clin. Vaccine Immunol. 18:506-512.
48. Vinogradov EV, Bock K, Holst O, Brade H. 1995. The structure of the lipid A-core region of the lipopolysaccharides from Vibrio cholerae O1 smooth strain 569B (Inaba) and rough mutant strain 95R (Ogawa). Eur. J. Biochem. 233:152-158.
49. Waldor MK, Colwell R, Mekalanos JJ. 1994. The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants. Proc. Natl. Acad. Sci. U. S. A. 91:11388-11392. (Pubitemid 24356349)
50. Wang J, et al. 1998. On the antigenic determinants of the lipopolysaccharides of Vibrio cholerae O:1, serotypes Ogawa and Inaba. J. Biol. Chem. 273:2777-2783. (Pubitemid 28133924)
51. WHO. 2010. Cholera vaccines: WHO position paper. Wkly. Epidemiol. Rec. 85:117-128.
52. Xu P, et al. 2011. Simple, direct conjugation of bacterial O-SP-core antigens to proteins: development of cholera conjugate vaccines. Bioconjug. Chem. 22:2179-2185.
53. Zuckerman JN, Rombo L, Fisch A. 2007. The true burden and risk of cholera: implications for prevention and control. Lancet Infect. Dis. 7:521-530. (Pubitemid 47079151)